Vimarsana
Biggest News Aggregation in the World

Page 22 - Preclinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Preclinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Preclinical Development Today - Breaking & Trending Today

Global COVID-19 Vaccines Market Research Report 2021: The Most Detailed Research Report to Date - Vimarsana News

Global COVID-19 Vaccines Market Research Report 2021: The Most Detailed Research Report to Date

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
AI-powered data specialist ScienceIO announces launch - Vimarsana News

AI-powered data specialist ScienceIO announces launch

The company has deployed with several healthcare firms, emerged from stealth, named a chief commercial officer, and landed investors backing the technology.

PharmSci 360 invites industry pros to 'rethink and evolve' - Vimarsana News

PharmSci 360 invites industry pros to 'rethink and evolve'

The conference (with online and in-person content) is slated to gather professionals for deep conversations and lively collaboration on important topics.

ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update - Vimarsana News

ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A - Vimarsana News

ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A

Press release content from Business Wire. The AP news staff was not involved in its creation. ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A July 8, 2021 GMT MILPITAS, Calif.--(BUSINESS WIRE)--Jul 7, 2021-- ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Drug Administration (FDA) has cleared an Inv...

Source: apnews.com